When Should We Start Using Angiotensin Converting Enzyme Inhibitors/Angiotensin Receptor Blockers in Diabetic Kidney Disease?

Journal Title: Нирки - Year 2017, Vol 6, Issue 1

Abstract

International guidelines do not recommend angiotensin converting enzyme (ACE) inhibitors/angiotensin receptor blockers (ARBs) usage in the first stage of diabetic kidney disease. It shows the view, based on a small statistical sample, that olmesartan (or possibly other ACE inhibitors/ARBs) should be used to prevent the transition of the first stage of diabetic kidney disease to the second one in type 2 diabetes mellitus.

Authors and Affiliations

D. D. Ivanov

Keywords

Related Articles

The experience of the Use of Essential Amino Acids and Their Keto-analogs in Children with Chronic Kidney Disease

This article explored the possibility of prolonged use of low-protein diet, 0.8 g/kg/day in combination with essential keto-analogs of amino acids in children with chronic kidney disease stage 4 to maximize the predialys...

Pharmacogenetic Tests in the Nephrological Clinic

Selection of antihypertensive agents using pharmacogenetic tests and individual tolerance is essential in practical nephrology. Antihypertensive first-line drugs are metabolized through various CYP isoforms (CYP2D6, CYP2...

Functional Renal Reserve: Physiological Value of Renal Reserve and Substantiation of the Method of Its Determination

In the article the authors have substantiated and shown the mechanisms of functional renal reserve actuation and its physiological meaning. There is dwelt the method of functional renal reserve determination. It was test...

CAKUT-Syndrome and Chronic Kidney Disease: the Concept of Nephrology Approach

This article presents the results of the analysis of the etiological structure of chronic kidney disease (CKD) in Kyiv children from 2006 to 2015. In the structure of CKD, CAKUT-syndrome dominates — from 62.3 % (2013) to...

Hemostatic System and its Regulation in Disorders of Renal Function

In various violations of kidney function, there is a change in the hemostatic system, which can manifest itself in the form of thrombosis or bleedings. In these processes, vascular endothelium, platelets, plasma proteins...

Download PDF file
  • EP ID EP208749
  • DOI 10.22141/2307-1257.6.1.2017.93781
  • Views 110
  • Downloads 0

How To Cite

D. D. Ivanov (2017). When Should We Start Using Angiotensin Converting Enzyme Inhibitors/Angiotensin Receptor Blockers in Diabetic Kidney Disease?. Нирки, 6(1), 31-35. https://europub.co.uk/articles/-A-208749